Rhythm Pharmaceuticals (RYTM) TD Cowen 46th Annual Health Care Conference summary

Strategic focus and pipeline overview

• Built around the melanocortin-4 pathway, with setmelanotide (IMCIVREE) as the lead molecule targeting rare genetic and acquired obesity disorders.

• Three pillars: genetic obesity (multiple genes), hypothalamic obesity (HO), and Prader-Willi syndrome, each with distinct development and commercialization strategies.

• Global approach emphasized, with ongoing expansion in the U.S., Europe, and Japan, leveraging claims data and KOL networks.

• Next-generation therapies in development, including daily oral and weekly injectable formulations, with promising phase II data.

• Basic science efforts continue through CRO partnerships to further understand and expand the pathway.

Regulatory and launch updates

• HO indication PDUFA date set for March 20, with all required efficacy and safety data submitted ahead of schedule.

• No post-market commitments required by FDA; labeling discussions are on track.

• Launch strategy for HO involves expanding the field force from 16 to 42, focusing on endocrinologists due to patient concentration.

• Over 2,000 HO patients identified (diagnosed and suspected), with numbers growing as awareness increases.

• Early launch trajectory expected to mirror Bardet-Biedl, with average three-month time from script to therapy, improving as payer policies adapt.

Market expansion and international strategy

• Japanese HO market estimated at 5,000–8,000 patients, higher prevalence than U.S.; direct presence being established with 40 staff by midyear.

• Centers of excellence and KOL networks are key to market entry and patient identification in Japan.